Solutions for pharma
One network, every stage of development
From first cohort to post-market evidence, Oku turns routine eye exams into trial-ready data, patients, sites, and answers. Start with the question you need answered; the network does the rest.
Join the Network
Built around how trials actually fail
Recruitment shortfalls, underperforming sites, endpoints that don't survive review. Each Oku solution attacks a specific point of failure in the development pipeline, and they compound: the same network that finds your patients generates your real-world evidence and reads your endpoints.
1
Real-World Data Access
Longitudinal retinal imaging and linked clinical data from primary eye care, specialty eye care, primary care, and health-screening networks. Enriched with AI-generated labels, expert annotation, and clinical diagnoses.
RWD Access
On-demand access to longitudinal patient data across Oku’s clinical network.
On-demand access to longitudinal patient data from optometry, ophthalmology, primary care, and health-screening networks. Enriched with AI-generated labels, expert annotation, and clinical diagnoses. Clients can run their own AI models on the dataset for insight generation and model validation. Available via IDHea.
RWD Transfer
A curated real-world cohort delivered to the customer’s environment.
A selected cohort of real-world data is licensed and transferred to the customer's environment for research and/or model training and validation. Delivered as an RWD Upload.
2
Real-World Evidence Generation
Consulting-style analytics run on Oku internal or externally-sourced datasets to answer scientific and commercial questions.
RWE via Oku Internal Data Sets
Evidence generation using Oku’s internal data inventory.
Consulting-style service to answer your scientific and/or commercial questions, with analytics for evidence generation run on datasets from Oku's internal inventory.
RWE via External Data Sets
Custom analytics on network datasets selected for specific requirements.
Consulting-style service to answer your questions, where Oku identifies data meeting your specific requirements from its network clinics and applies analytics for evidence generation.
Cohort Enrichment
Matched real-world controls that strengthen an existing study population.
Augment an existing study population with matched real-world controls.
3
Patient and Site Finder
Find the patients and the sites that make trials work: treatment-naïve patients having routine eye exams, and sites chosen on verified patient density, not anecdote.
Patient Identification
AI screening to find eligible, treatment-naïve patients in routine care.
Deploys AI eligibility screening, analyzing retinal imaging alongside clinical data, retrospectively and prospectively in primary eye care and primary care settings where early-stage, treatment-naïve patients are present. Reduces screen failure while unlocking a larger patient pool.
Patient Recruiting
Consent, outreach, and enrollment support for formal trial screening.
Full-service patient enrollment support: consent, outreach, and enrollment for formal trial screening.
Site Feasibility Assessment
Verified patient-density analysis to identify stronger trial sites.
Deploys EMR- and image-based AI across your trial-site network and selects sites based on verified real-patient density and eligibility fit, replacing selection based on anecdotal site relationships and historical performance.
Site Discovery
New trial-site opportunities outside the customer’s current network.
Identifies new potential trial sites not currently in your network.
4
Reading Center Services
Centralized, reproducible adjudication of trial imaging that cuts inter-reader variability and speeds regulatory submissions.
Hybrid Reading Center Service
Centralized AI-plus-expert adjudication for trial imaging.
Centralized adjudication of imaging and functional trial data using standardized methodologies. A hybrid reading model combining AI and human expert reading reduces variability, safeguards data integrity, and accelerates regulatory submissions for drugs and devices.
Start with the question
Whether the question is "where are our patients?" or "will this endpoint hold?" the network probably holds the answer